About Torrent Pharma and its Mexican Market Importance
Torrent Pharma, an Indian pharmaceutical company, is looking to acquire a Mexican firm that generates around $150 million annually and operates in therapeutic areas such as oncology, mental health, cardiology, and diabetes. Mexico is Torrent Pharma’s fourth-largest market outside of India, where 60% of its revenue is generated. It ranks behind the United States, Germany, and Brazil.
Acquisition Targets and Investment Opportunities
Jorge Barreto, Torrent Pharma’s General Manager for Mexico and Latin America, stated that they are interested in acquiring a company primarily in Mexico but would also consider opportunities in Colombia or Chile if they align with their Mexican expansion strategy. Barreto also mentioned openness to investment opportunities in pharmaceutical companies developing therapies for obesity and women’s health, provided they meet good manufacturing practices and regulatory requirements.
Mexico’s Significance and Future Plans
Barreto emphasized that Mexico is one of the emerging countries where Torrent Pharma prioritizes investment due to its potential and healthcare needs. The company has been operating in the Mexican private market for 15 years, serving national pharmacy chains and wholesalers catering to independent pharmacies.
No Immediate Interest in Public Tenders
Although they are not currently participating in Mexico’s government public tenders, Torrent Pharma remains open to doing so in the future. Their primary interest lies in expanding their private sector business, understanding that introducing areas like oncology will create significant opportunities in the institutional channel.
Quality and Affordable Medicines
Barreto highlighted that Torrent Pharma offers high-quality medicines at affordable prices, aligning with the current federal administration’s interests. The company operates seven manufacturing plants, all certified by the U.S. Food and Drug Administration (FDA), Brazil’s National Health Surveillance Agency (ANVISA), and the European Medicines Agency (EMA).
Long-Term Investments in Mexico
With 15 years of presence in Mexico, Torrent Pharma invests between 250 and 300 million pesos annually in its operations, including continuous medical education programs. Recent investments include around 20 million pesos for new offices in Mexico City and 10 million pesos for developing their TYSA platform, an AI-based tool supporting medical education for future psychiatrists and neurologists.
TYSA Platform: An AI-Powered Medical Education Tool
The TYSA platform offers free access to medical content, summaries, and study guides tailored to users’ academic profiles in formats like podcasts or videos. Integrated with WhasApp, it delivers content directly to users’ mobile devices. As Torrent Pharma expands into new therapeutic areas, TYSA is expected to cover related conditions.
Key Questions and Answers
- What is Torrent Pharma’s primary goal in Mexico? Expanding their private sector business and introducing therapeutic areas like oncology to tap into institutional opportunities.
- What therapeutic areas is Torrent Pharma interested in? Oncology, mental health, cardiology, diabetes, obesity, and women’s health.
- How does Torrent Pharma ensure the quality of its medicines? Their seven manufacturing plants are certified by FDA, ANVISA, and EMA.
- What recent investments has Torrent Pharma made in Mexico? They invested around 20 million pesos in new offices and 10 million pesos in the TYSA platform, an AI-based medical education tool.
- What is the TYSA platform and how does it benefit users? TYSA offers free access to tailored medical content, summaries, and study guides in various formats. It integrates with WhatsApp for direct delivery to mobile devices.
